In The News

The Myeloma Crowd Multiple Myeloma Research, Funding, News, Tips and Help

  • ASH 2019: Early or Delayed Stem Cell Transplant in Multiple Myeloma
    by Jenny A on December 6, 2019 at 11:16 pm

    The Friday symposiums before the American Society of Hematology meeting are some of the best reasons to attend the conference. In one morning session, several myeloma “debates” were presented with two doctors each taking a contrasting opinion. The debate still rages – should myeloma patients go immediately to transplant or wait until they relapse?  Amrita […]

  • ASH 2019: The Debate Heats Up Over Treating High Risk Smoldering Multiple Myeloma
    by Bonnie Falbo on December 6, 2019 at 11:11 pm

        Today at the American Society of Hematology 2019 conference in an MMRF session “Current Obstacles in Myeloma Management: Debating the Evidence, Dr. Saad Usmani and Dr. Rafael Fonseca faced off on the question “Should Smoldering Myeloma be Treated”?   Answer: At this time there is not enough agreement among Myeloma specialists to answer […]

  • Updated #ASH19 Myeloma GUIDE! 11 Myeloma Specialists Choose Their Favorite Topics
    by Gary Petersen on December 5, 2019 at 7:18 pm

    Myeloma Crowd provides the final pre #ASH19 listing of the most relevant myeloma abstracts. The listing is intended to let the participants with an interest in myeloma to find and attend the most important oral presentations. In addition, anyone following ASH by way of the internet can click on the abstracts to see what is […]

  • What is the American Society of Hematology (ASH) Meeting?
    by Vicki Jones on December 4, 2019 at 9:51 pm

    There are around 120,000 people in this country living with multiple myeloma. About 32,000 of those were diagnosed within the last year. It’s understandable, then, that a great number of Myeloma patients have no idea what “ASH” is. I’m sure you know that Myeloma is a blood disease and doctors who specialize in blood diseases […]

  • Myeloma Crowd Round Table Expert Videos: Atlanta — October 12, 2019
    by Erika Johnson on December 4, 2019 at 7:03 pm

    On October 12, 2019, a Myeloma Crowd Round Table meeting was held in Atlanta, Georgia at the Emory Conference Center Hotel featuring five myeloma experts, including: Dr. Morie Gertz, Mayo Clinic, Rochester, MN Dr. Craig Hofmeister, Winship Cancer Institute, Atlanta, GA Dr. Nisha Joseph, Winship Cancer Institute, Atlanta, GA Dr. Jonathan Kaufman, Winship Cancer Institute, […]

Myeloma Research News The Web’s Daily Resource for Myeloma Research News

  • Ninlaro Triple Combo Delays Progression of High-Risk Smoldering Multiple Myeloma, Trial Suggests
    by Iqra Mumal, MSc on December 6, 2019 at 1:00 pm

    Early treatment with a triple combination therapy containing Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone in patients with high-risk smoldering multiple myeloma — a precursor of multiple myeloma — is safe and may halt the disease’s progression into the full-blown condition, a Phase 2 trial shows. The results will be presented at the American Society of Hematology The post Ninlaro Triple Combo Delays Progression of High-Risk Smoldering Multiple Myeloma, Trial Suggests appeared first on Myeloma Research News.

  • Venclexta Safe and Effective for Certain Multiple Myeloma Patients, Trial Data Show
    by Patricia Inacio, PhD on December 3, 2019 at 10:45 pm

    Venclexta (venetoclax), approved to treat lymphoma and leukemia, may also be promising for multiple myeloma patients who failed at least one prior treatment, particularly those with a common genetic abnormality called t(11;14) or with high levels of the cell survival protein BCL2, data from two studies suggest. Findings in these studies will soon be presented at The post Venclexta Safe and Effective for Certain Multiple Myeloma Patients, Trial Data Show appeared first on Myeloma Research News.

  • Ygalo Continues to Show Positive Results in RRMM Patients, Oncopeptides Announces
    by Joana Carvalho, MSc on December 2, 2019 at 1:00 pm

    Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients with relapsed or refractory multiple myeloma (RRMM), according to the latest results from clinical trials. Data from the clinical program of Ygalo and multiple myeloma’s impact on quality of life will be presented at the American Society of Hematology (ASH) 2019 The post Ygalo Continues to Show Positive Results in RRMM Patients, Oncopeptides Announces appeared first on Myeloma Research News.

  • AbbVie Obtains Global Rights Option for HPN217, Phase 1/2 Trial in Multiple Myeloma Planned
    by Iqra Mumal, MSc on November 27, 2019 at 1:00 pm

    Harpoon Therapeutics has granted AbbVie an option for exclusive worldwide rights to HPN217, a treatment candidate for people with multiple myeloma, after the completion of an anticipated Phase 1/2 trial. The companies plan to file an investigational new drug application for HPN217 with the U.S. Food and Drug Administration before the end of the year. If The post AbbVie Obtains Global Rights Option for HPN217, Phase 1/2 Trial in Multiple Myeloma Planned appeared first on Myeloma Research News.

  • BiCNU Generic for Multiple Myeloma, Other Cancers Launched in US
    by Marta Figueiredo on November 25, 2019 at 3:00 pm

    Carmustine for Injection, a generic version of the chemotherapy BiCNU, has been launched in the U.S to treat people with multiple myeloma and other types of cancer. This follows the decision by the U.S. Food and Drug Administration (FDA) to approve STI Pharma‘s abbreviated new drug application — specific to generic medicines — for this product. Generic The post BiCNU Generic for Multiple Myeloma, Other Cancers Launched in US appeared first on Myeloma Research News.

Myeloma Research News The Web’s Daily Resource for Myeloma Research News

  • Ninlaro Triple Combo Delays Progression of High-Risk Smoldering Multiple Myeloma, Trial Suggests
    by Iqra Mumal, MSc on December 6, 2019 at 1:00 pm

    Early treatment with a triple combination therapy containing Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone in patients with high-risk smoldering multiple myeloma — a precursor of multiple myeloma — is safe and may halt the disease’s progression into the full-blown condition, a Phase 2 trial shows. The results will be presented at the American Society of Hematology The post Ninlaro Triple Combo Delays Progression of High-Risk Smoldering Multiple Myeloma, Trial Suggests appeared first on Myeloma Research News.

  • Venclexta Safe and Effective for Certain Multiple Myeloma Patients, Trial Data Show
    by Patricia Inacio, PhD on December 3, 2019 at 10:45 pm

    Venclexta (venetoclax), approved to treat lymphoma and leukemia, may also be promising for multiple myeloma patients who failed at least one prior treatment, particularly those with a common genetic abnormality called t(11;14) or with high levels of the cell survival protein BCL2, data from two studies suggest. Findings in these studies will soon be presented at The post Venclexta Safe and Effective for Certain Multiple Myeloma Patients, Trial Data Show appeared first on Myeloma Research News.

  • Ygalo Continues to Show Positive Results in RRMM Patients, Oncopeptides Announces
    by Joana Carvalho, MSc on December 2, 2019 at 1:00 pm

    Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients with relapsed or refractory multiple myeloma (RRMM), according to the latest results from clinical trials. Data from the clinical program of Ygalo and multiple myeloma’s impact on quality of life will be presented at the American Society of Hematology (ASH) 2019 The post Ygalo Continues to Show Positive Results in RRMM Patients, Oncopeptides Announces appeared first on Myeloma Research News.

  • AbbVie Obtains Global Rights Option for HPN217, Phase 1/2 Trial in Multiple Myeloma Planned
    by Iqra Mumal, MSc on November 27, 2019 at 1:00 pm

    Harpoon Therapeutics has granted AbbVie an option for exclusive worldwide rights to HPN217, a treatment candidate for people with multiple myeloma, after the completion of an anticipated Phase 1/2 trial. The companies plan to file an investigational new drug application for HPN217 with the U.S. Food and Drug Administration before the end of the year. If The post AbbVie Obtains Global Rights Option for HPN217, Phase 1/2 Trial in Multiple Myeloma Planned appeared first on Myeloma Research News.

  • BiCNU Generic for Multiple Myeloma, Other Cancers Launched in US
    by Marta Figueiredo on November 25, 2019 at 3:00 pm

    Carmustine for Injection, a generic version of the chemotherapy BiCNU, has been launched in the U.S to treat people with multiple myeloma and other types of cancer. This follows the decision by the U.S. Food and Drug Administration (FDA) to approve STI Pharma‘s abbreviated new drug application — specific to generic medicines — for this product. Generic The post BiCNU Generic for Multiple Myeloma, Other Cancers Launched in US appeared first on Myeloma Research News.